Company Filing History:
3 out of 115 
1 out of 4,770 
1 out of 2,405 
Years Active: 2002-2023
Title: Mark Bruner: Innovator in HIV Vaccine Development
Introduction
Mark Bruner is a notable inventor based in Norristown, PA (US). He has made significant contributions to the field of immunology, particularly in the development of HIV vaccines. With a total of 5 patents to his name, Bruner's work is recognized for its potential impact on public health.
Latest Patents
Bruner's latest patents focus on innovative HIV vaccine formulations. These immunogenic compositions contain a human immunodeficiency virus (HIV) gp140 protein, sorbitol, polysorbate 20, and a histidine buffer. The compositions are designed to be stable at refrigerated temperatures for extended periods, making them advantageous for storage and distribution. Additionally, they are compatible with adjuvants, enhancing their effectiveness. The methods described in his patents also include ways to use these immunogenic compositions to induce an immune response against HIV in subjects. They can be administered alone or in combination with additional HIV antigens or adenovirus vectors encoding these antigens.
Career Highlights
Throughout his career, Mark Bruner has worked with prominent companies in the pharmaceutical industry. He has been associated with Janssen Vaccines & Prevention B.V. and Merck & Co., Inc. His experience in these organizations has contributed to his expertise in vaccine development and immunology.
Collaborations
Bruner has collaborated with notable colleagues in his field, including Thierry-Thien Nguyen and Robert K. Evans. These partnerships have likely enhanced the quality and scope of his research and innovations.
Conclusion
Mark Bruner's contributions to HIV vaccine development highlight his role as an influential inventor in the field of immunology. His innovative approaches and collaborations continue to pave the way for advancements in vaccine technology.